<DOC>
	<DOCNO>NCT02934464</DOCNO>
	<brief_summary>This randomize , open-label , multicenter phase III trial ramucirumab plus paclitaxel , give switch maintenance , versus continuation first-line chemotherapy , give per standard clinical practice , subject unresectable locally advanced metastatic HER-2 negative gastric GEJ cancer , without disease progression follow 3 month first-line doublet chemotherapy . The acceptable first-line lead-in chemotherapy : - FOLFOX4 : Oxaliplatin 85 mg/m2 . l-Leucovorin 100 mg/m2 5-fluorouracil 400/600 mg/m2 . Cycle length 2 week +/- 3 day . - ModifiedFOLFOX6 : Oxaliplatin 85 mg/m2 . l-Leucovorin 200 mg/m2 . 5-fluorouracil 400 mg/m2 2400 mg/m2 46-hours continous infusion . Cycle length 2 week +/- 3 day . - XELOX : Oxaliplatin130 mg/m2.Capecitabine 2000 mg/m2 14 day . Cycle length 3 week +/- 3 day .</brief_summary>
	<brief_title>Assessment Ramucirumab Plus Paclitaxel Switch MANteInance Versus Continuation First-line Chemotherapy Patients With Advanced HER-2 Negative Gastric Gastroesophageal Junction Cancers : ARMANI Phase III Trial</brief_title>
	<detailed_description>Treatment must continue 4 three-weekly cycle 6 bi-weekly cycle , maximum 12 week . Subjects CR/PR/SD oxaliplatinum compound fluoropyrimidine-based regimen , without evidence progressive disease case non-measurable disease , randomize 1:1 ratio two treatment arm . Prior randomization , subject stratify base Center ; Prior gastrectomy : No v . Yes ; Peritoneal carcinomatosis : Yes vs. No ; Site origin : GEJ vs. gastric .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Patients must meet follow criterion study entry : 1 . Written inform consent prior performance study procedure ; 2 . Age ≥18 year ; 3 . ECOG Performance Status 01 ( Appendix I ) ; 4 . Life expectancy least 12 week opinion Investigator ; 5 . Unresectable locally advanced metastatic , histopathologically confirm , HER2 negative adenocarcinoma gastric GEJ cancer measurable and/or evaluable disease base RECIST , v1.1 6 . Must receive leadin chemotherapy firstline set use one fluoropyrimidines oxaliplatinbased doublet combination specify Section 7 continue three month ( i.e . 6 administration biweekly cycle regimens 4 administration threeweekly cycle regimen ) . Patients receive adjuvant cisplatin/oxaliplatin plus fluoropyrimidinebased doublet chemotherapy recurrence beyond 12 month completion eligible . 7 . Must radiological evidence clinical benefit follow last dose leadin chemotherapy ( either CR , PR SD RECIST v1.1 criterion case measurable disease , absence progressive disease case nonmeasurable disease ) . 8 . Laboratory requirement : The patient adequate hematologic function , evidence absolute neutrophil count ( ANC ) ≥1000/µL , hemoglobin ≥9 g/dL ( 5.58 mmol/L ) , platelets ≥100,000/µL . The patient adequate hepatic function define total bilirubin ≤1.5 mg/dL ( 25.65 μmol/L ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 time upper limit normal ( ULN ; 5.0 time ULN set liver metastasis ) . The patient adequate renal function define serum creatinine ≤1.5 time ULN , creatinine clearance ( measure via 24hour urine collection ) ≥40 mL/minute ( , serum creatinine &gt; 1.5 time ULN , 24hour urine collection calculate creatinine clearance must perform ) . The patient 's urinary protein ≤1+ dipstick routine urinalysis ( UA ; urine dipstick routine analysis ≥2+ , 24hour urine collection protein must demonstrate &lt; 1000 mg protein 24 hour allow participation protocol ) . Coagulation : The patient must adequate coagulation function define International Normalized Ratio ( INR ) ≤ 1.5 , partial thromboplastin time ( PTT ) ≤ 5 second ULN ( unless receive anticoagulation therapy ) . Patients receive warfarin must switch low molecular weight heparin achieve stable coagulation profile prior randomization 9 . Patients must accessible treatment follow . Patients register trial must treat follow participate center . 10 . Archival tumor tissue require exploratory research enrollment . 11 . Because teratogenicity ramucirumab know , patient , sexually active , must postmenopausal , surgically sterile , use effective contraception ( hormonal barrier method ) entire duration study include minimum 12 week dose complete . Female patient childbearing potential must negative serum pregnancy test within 7 day prior enrolment . Women must breastfeed . Exclude patient study follow condition observe : 1 . HER2 positive status , patient squamous cell . 2 . Prior malignancy , active within 3 year study entry , except locally curable cancer apparently cure need subsequent therapy , nonmelanoma skin cancer , superficial bladder cancer cancer situ breast cervix . 3 . Has serious illness medical condition ( ) include , limited following : 1 . Known brain metastasis leptomeningeal metastasis . 2 . Active infection ( ie , body temperature ≥38°C due infection ) . 3 . Ascites , pleural effusion pericardial fluid require drainage last 4 week . 4 . Intestinal obstruction , pulmonary fibrosis interstitial pneumonitis , renal failure , liver failure , cerebrovascular disorder . 5 . Uncontrolled diabetes . 6 . The patient symptomatic congestive heart failure ( New York Heart Association IIIV ) symptomatic poorly control cardiac arrhythmia . 7 . The patient experience arterial thrombotic event , include myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack , within 6 month prior randomization . 8 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness , hepatitis B C. 9 . Autoimmune disorder history organ transplantation require immunosuppressive therapy . l.Psychiatric disease may increase risk associate study participation study drug administration , may interfere interpretation study result . m.The patient history deep vein thrombosis , pulmonary embolism , significant thromboembolism ( venous port catheter thrombosis superficial venous thrombosis consider `` significant '' ) 3 month prior randomization . n.The patient receive therapeutic anticoagulation warfarin , lowmolecular weight heparin similar agent . Patients receive prophylactic , lowdose anticoagulation therapy eligible provide coagulation parameter define inclusion criterion ( INR ≤ 1.5 aPTT ≤ 1.5 x ULN ) ( PT ≤ 1.5 x ULN aPTT ≤1.5 x ULN ) meet . o.The patient receive chronic therapy nonsteroidal antiinflammatory agent ( NSAIDs , eg , indomethacin , ibuprofen , naproxen similar agent ) antiplatelet agent ( eg , clopidogrel , ticlopidine , dipyridamole , anagrelide ) . Aspirin use dose 325 mg/day permit . p.The patient significant bleeding disorder , vasculitis , significant bleeding episode gastrointestinal tract within 3 month prior study entry . q.History gastrointestinal perforation and/or fistula within 6 month prior randomization . r.The patient bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection ( hemicolectomy extensive small intestine resection chronic diarrhea ) , Crohn 's disease , ulcerative colitis , chronic diarrhea . s.The patient uncontrolled arterial hypertension ≥ 150 / ≥ 90 mm Hg despite standard medical management . t.The patient serious non heal wound peptic ulcer bone fracture within 28 day prior randomization . u.Known allergy hypersensitivity monoclonal antibody treatment component use ramucirumab DP preparation . Known allergy hypersensitivity paclitaxel component use paclitaxel preparation contraindication taxane therapy . v.Persistent proteinuria CTCAE Grade 3 ( &gt; 3.5g/24 hour ) . 4 . Treatment follow within specified time frame prior study drug administration : 1 . Major surgery within 28 day prior randomization , central venous access device placement within 7 day prior randomization . 2 . Any investigational agent include VEGF VEGFRtargeted agent within prior 4 week 3 . Extended field radiation within prior 4 week limited field radiation within prior 2 week . 5 . Unresolved toxicity great equal CTCAE Grade 2 attribute prior therapy ( exclude anemia , alopecia , skin pigmentation ) . In particular , patient platinum induced neurotoxicity great equal CTCAE Grade 2 resolve induction phase exclude . 6 . Is pregnant lactate female , plan become pregnant treatment within 12 week end treatment ramucirumab . Women childbearing potential either positive pregnancy test baseline . Women childbearing potential sexually active men willing use contraception study least 12 week end treatment ramucirumab . Postmenopausal woman must amenorrheic least 12 month consider nonchild bear potential . 7 . Concomitant participation participation within last 30 day another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>